Eli Lilly
Q4 2022 Earnings Call
Feb 02, 2023, 10:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2022 earnings conference call. [Operator instructions] Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator instructions] And as a reminder, today's conference is being recorded. I would now like to turn the conference over to our host, Joe Fletcher, senior vice president of investor relations.
Please go ahead.
Joe Fletcher -- Senior Vice President, Investor Relations
Thank you, Lois. Good morning and thank you all for joining us for Eli Lilly and Company's Q4 2022 earnings call. I'm Joe Fletcher, and joining me on today's call are Dave Ricks, Lilly's chair and CEO; Anat Ashkenazi, chief financial officer; Dr. Dan Skovronsky, chief scientific and medical officer; Anne White, president of Lilly Neuroscience; Ilya Yuffa, president of Lilly International; Jake Van Naarden, CEO of Loxo at Lilly; Mike Mason, president of Lilly Diabetes; and Patrik Jonsson, president of Lilly Immunology and Lilly USA.
We're also joined by Mike Sprengnether, Kento Ueha, and Lauren Zierke from the investor relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 3. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission.
The information we provide about our products and pipeline is for the benefit of the investment community. It's not intended to be promotional and it's not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures. And now, I'll turn the call over to Dave.
Dave Ricks -- Chairman and Chief Executive Officer
OK. Thanks, Joe. 2022 was a year of strong pipeline and commercial performance for Lilly. We delivered top- and bottom-line growth in 2022 despite the impact of the Alimta LOE in the U.S.
and significant FX headwinds and delivered another remarkable year of pipeline progress. We began 2023 with multiple updates to our late-stage pipeline. In our Q2 2022 earnings call last August, we announced the filing of submissions for two assets with the FDA under an accelerated approval pathway: pirtobrutinib in mantle cell lymphoma and donanemab in early symptomatic Alzheimer's disease. Last month, we received a response from the FDA on both of these assets.